# Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

> **NCT00976248** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 33 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00976248
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2016-07
- **Final completion:** 2018-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2018-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976248, "Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00976248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*